[go: up one dir, main page]

WO1999060406A1 - Myo-inositol utilise en tant que predicteur de la regulation de la glycemie chez des mammiferes - Google Patents

Myo-inositol utilise en tant que predicteur de la regulation de la glycemie chez des mammiferes Download PDF

Info

Publication number
WO1999060406A1
WO1999060406A1 PCT/US1999/011201 US9911201W WO9960406A1 WO 1999060406 A1 WO1999060406 A1 WO 1999060406A1 US 9911201 W US9911201 W US 9911201W WO 9960406 A1 WO9960406 A1 WO 9960406A1
Authority
WO
WIPO (PCT)
Prior art keywords
inositol
sample
glycemic control
mammal
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/011201
Other languages
English (en)
Inventor
Geoffrey Allan
John J. Oprandy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Insmed Pharmaceuticals Inc
Original Assignee
Insmed Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insmed Pharmaceuticals Inc filed Critical Insmed Pharmaceuticals Inc
Priority to AU40914/99A priority Critical patent/AU4091499A/en
Publication of WO1999060406A1 publication Critical patent/WO1999060406A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose

Definitions

  • This invention relates to methods of assessing glycemic control in mammals with Type II
  • diabetes by measuring the level of my ⁇ -inositol in body fluid.
  • MI yo-inositol
  • Sources of MI for the human body generally consist of
  • Non-obese GK (Goto-Kazizaki) rats with Type II diabetes have been shown to manifest insulin
  • Glycemic control i.e. the maintenance of normal or near-
  • normal blood sugar levels may involve diet, exercise, and weight reduction, as well as blood
  • MI levels have not been used to detect the degree of diabetes or glycemic
  • the present invention is based, in part, on the discovery that levels of MI in bodily fluids correlate to known and well accepted indicators of glycemic control in mammals with Type II
  • a first embodiment of the present invention is directed to a method for assessing the degree of glycemic control in a mammal. This method comprises the steps of: (a)
  • FIGURE 1 is a graph showing the significant (P ⁇ 0.0001) correlation between urinary MI levels and fasting blood glucose levels.
  • FIGURE 2 is a graph showing the significant (PO.0001) correlation between urinary MI levels and blood fructosamine levels.
  • FIGURE 3 is a graph showing the significant (P ⁇ 0.0001) correlation between urinary MI
  • Type II diabetes mellitus has been diagnosed by finding an elevated fasting
  • a first preferred embodiment of the present invention is directed to a method
  • This method comprises the steps of:
  • the mammalian bodily fluid is blood or urine;
  • the mammalian bodily fluid is urine.
  • the sample of a bodily fluid may be taken from the mammalian subject without regard to
  • the sample of a bodily fluid may be a
  • spot sample i.e. a sample taken at any time during the day, with or without a preceding fast
  • 24-hour sample a fasted overnight sample
  • the level of MI in the sample can be measured by any of the analytical procedures known
  • HPLC high-performance liquid chromatography
  • CE capillary electrophoresis
  • the level of MI in the sample is measured by an enzyme assay.
  • the level of MI in the sample is determined as:
  • the lower reference level for a spot urine sample is in the range
  • MI levels below this lower reference level indicate good glycemic control.
  • the upper reference level for a spot urine sample is in the
  • MI levels above this upper reference level indicate poor glycemic control. It should be pointed out, however, that these exemplary levels are from one specific
  • EXAMPLE l A STUDY OF URINARY MYO-INOSITOL LEVELS IN PATIENTS WITH TYPE II DIABETES
  • MI levels were measured in the urine samples by a gas chromatography/mass

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Food Science & Technology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Cette invention concerne des procédés qui permettent d'évaluer la régulation de la glycémie chez des mammifères atteints du diabète du type II, ces procédés consistant à mesurer le taux de myo-inositol dans du fluide corporel.
PCT/US1999/011201 1998-05-21 1999-05-21 Myo-inositol utilise en tant que predicteur de la regulation de la glycemie chez des mammiferes Ceased WO1999060406A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU40914/99A AU4091499A (en) 1998-05-21 1999-05-21 (myo)-inositol as a predictor of glycemic control in mammals

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8254298A 1998-05-21 1998-05-21
US09/082,542 1998-05-21

Publications (1)

Publication Number Publication Date
WO1999060406A1 true WO1999060406A1 (fr) 1999-11-25

Family

ID=22171854

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/011201 Ceased WO1999060406A1 (fr) 1998-05-21 1999-05-21 Myo-inositol utilise en tant que predicteur de la regulation de la glycemie chez des mammiferes

Country Status (2)

Country Link
AU (1) AU4091499A (fr)
WO (1) WO1999060406A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6518318B1 (en) 1999-05-20 2003-02-11 Charles E. Weeks Stimulating transport of glucose into animal tissue by the administration of pinitol
US7452687B2 (en) 2002-03-29 2008-11-18 Asahi Kasei Pharma Corporation Method of detecting mild impaired glucose tolerance or insulin secretory defect
WO2009109647A1 (fr) * 2008-03-05 2009-09-11 Gunnar Norstedt Procédé de surveillance d'un état métabolique par mesure de l'inositol phosphate
EP2877602A4 (fr) * 2012-06-05 2016-04-20 Medical Res Infrastructure & Health Services Fund Nouveau dosage pour la surveillance de l'équilibre du glucose et du stress oxydatif

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996001996A1 (fr) * 1994-07-08 1996-01-25 The University Of Virginia Patent Foundation Procede de detection de la resistance a l'insuline

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996001996A1 (fr) * 1994-07-08 1996-01-25 The University Of Virginia Patent Foundation Procede de detection de la resistance a l'insuline

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 85, no. 19, 8 November 1976, Columbus, Ohio, US; abstract no. 139388, L. WALDEMAR ET AL.: "A simple method for the quantitative determination of myoinositol in serum and urine." page 226; column 2; XP002114802 *
E. PITKÄNEN: "The serum polyol pattern and the urinary polyol excretion in diebetic and in uremic patients.", CLINICA CHIMICA ACTA, vol. 38, 1972, Amsterdam, NL., pages 221 - 230, XP002114800 *
M. HASEGAWA ET AL.: "Measurement of myo-inositol in diabetic sera by GC/MS/SIM using n-butylboronate derivatives.", CLINICA CHIMICA ACTA, vol. 176, 1988, Amsterdam, NL., pages 207 - 212, XP002114801 *
POL. TYG. LEK., vol. 31, no. 17, 1976, pages 711 - 713 *
R. DOLHOFER ET AL.: "Enzymatic assay of myo-inositol in serum.", JOURNAL OF CLINICAL CHEMISTRY AND CLINICAL BIOCHEMISTRY, vol. 25, no. 10, 1987, Berlin, DE, pages 733 - 736, XP002114799 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6518318B1 (en) 1999-05-20 2003-02-11 Charles E. Weeks Stimulating transport of glucose into animal tissue by the administration of pinitol
US7452687B2 (en) 2002-03-29 2008-11-18 Asahi Kasei Pharma Corporation Method of detecting mild impaired glucose tolerance or insulin secretory defect
WO2009109647A1 (fr) * 2008-03-05 2009-09-11 Gunnar Norstedt Procédé de surveillance d'un état métabolique par mesure de l'inositol phosphate
EP2877602A4 (fr) * 2012-06-05 2016-04-20 Medical Res Infrastructure & Health Services Fund Nouveau dosage pour la surveillance de l'équilibre du glucose et du stress oxydatif

Also Published As

Publication number Publication date
AU4091499A (en) 1999-12-06

Similar Documents

Publication Publication Date Title
Krolewski et al. Risk of early-onset proliferative retinopathy in IDDM is closely related to cardiovascular autonomic neuropathy
Barnardo et al. Renal function, renin activity and endogenous vasoactive substances in cirrhosis
EP1425582B1 (fr) Marqueurs diagnostiques de l'ischemie et risque de mortalite
EP1111387B1 (fr) Procede de detection des maladies du rein et procede de surveillance pathologique
Lin Clinical significance of serum creatinine, urea Nitrogen and uric acid levels in patients with chronic renal failure
CA2216380C (fr) Methode de determination des clairances renales
WO1999060406A1 (fr) Myo-inositol utilise en tant que predicteur de la regulation de la glycemie chez des mammiferes
Wu et al. Circulating total and ionized magnesium after ethanol ingestion
Yamaguchi et al. Evaluation of time-course changes of gingival crevicular fluid glucose levels in diabetics
JP2004501366A (ja) 患者の全血、血漿および（または）血清中のアルファ・オキソアルデヒドを検出する方法
Tomaselli et al. Evaluation of albumin excretion rate in overnight versus 24-h urine
Loste et al. Clinical value of fructosamine measurements in non-healthy dogs
Venos et al. Endocrine markers of diabetes and cardiovascular disease risk
Bennett et al. Postmortem recognition of fatty acid oxidation disorders
Nosadini et al. Peripheral, rather than hepatic, insulin resistance and atherogenic lipoprotein phenotype predict cardiovascular complications in NIDDM
JP2025531776A (ja) Ｍｉｄｄの診断方法および試薬キット
Dharmakeerthi et al. Correlation Between Blood Glucose and Salivary Glucose in Type 2 Diabetes Mellitus Patients.
Elio et al. Effects of acute, heavy-resistance exercise on urinary peptide hormone excretion in humans
McCance et al. Serum fructosamine in uraemia, myeloma and acute inflammatory disorders—relationship to serum glucose and albumin levels
Chowdhry et al. Study of glycaemic biomarkers in the patients of thyroid disorders
Vermes et al. The role of serum fructosamine as a screening test for gestational diabetes mellitus
RU2230326C2 (ru) Способ диагностики тканевой инсулинорезистентности у различной категории кардиологических больных
KANAUCHI et al. Effect of exercise on hemodynamics and urinary protein excretion in patients with early-stage diabetic nephropathy
Marczewski et al. Particular fractions of microproteinuria in patients with stabile angina pectoris and without a clinical nephropathy
Soriano et al. Relationship between Fructosamine Levels and Microalbuminuria of Selected Individuals with Type 2 Diabetes Mellitus

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase